High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/27811

Title:	High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Authors:	Alba, Emilio Lluch, Ana Ribelles, Nuria Anton-Torres, Antonio Sanchez-Rovira, Pedro Albanell, Joan Calvo, Lourdes García-Asenjo, Jose Antonio Lopez Palacios, Jose Chacon, Jose Ignacio Ruiz, Amparo De la Haba-Rodriguez, Juan Segui-Palmer, Miguel A Cirauqui, Beatriz Margeli, Mireia Plazaola, Arrate Barnadas, Agusti Casas, Maribel Caballero, Rosalia Carrasco, Eva Rojo, Federico View more
Keywords:	Breast cancer Chemosensitivity Ki67 Neoadjuvant chemotherapy Predictive factor View more
Mesh:	Adult Aged Breast Neoplasms Clinical Trials as Topic Disease-Free Survival Estrogen Receptor alpha Female Humans Ki-67 Antigen Middle Aged Neoadjuvant Therapy Neoplasm Staging Predictive Value of Tests Prognosis Receptor, ErbB-2 View more
Issue Date:	Feb-2016
Citation:	Oncologist.2016 Feb;(21)2:150-5
Abstract:	In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary endocrine treatment efficacy, but its value as a predictor of response to chemotherapy is still controversial.
PMID:	26786263
URI:	https://hdl.handle.net/20.500.12530/27811
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC4746087.pdf		624.19 kB	Adobe PDF	View/Open